TSLP and asthma: Regarding the medium-term respiratory morbidity, the detection of nasal TSLP was significantly associated with the prescription of maintenance asthma treatment (p = 0.04), prescription of montelukast (p = 0.01), and the combination montelukast plus inhaled glucocorticosteroids (IGC) (p = 0.03).